(Q43601291)

English

A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

based on heuristic

inferred from title

author name string

Darin A Wick

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

John R Webb

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

2 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

7857-7866

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Papillomaviruses and cancer: from basic studies to clinical application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Chapter 2: The burden of HPV-related cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Case-control study of human papillomavirus and oropharyngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Human papillomavirus (HPV) in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Human papilloma virus is associated with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Prevention of cervical cancer through papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

HPV vaccination for the prevention of cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Therapeutic vaccines against human papillomavirus and cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Therapeutic HPV DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Therapeutic human papillomavirus vaccines: current clinical trials and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

A simple but effective cancer vaccine consisting of an antigen and a cationic lipid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Viral immunity: cross-priming with the help of TLR3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Toll-like receptor 3 promotes cross-priming to virus-infected cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Conjugation of 3' hexameric deoxyriboguanosine run to phosphodiester CpG oligodeoxynucleotides can inhibit allergen-specific IgE synthesis with less risk of splenomegaly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Regulation of immune responses to HPV infection and during HPV-directed immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.090

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.07.090

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43601291&oldid=2101823245"